68 related articles for article (PubMed ID: 12432548)
1. Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study.
Schraa AJ; Kok RJ; Moorlag HE; Bos EJ; Proost JH; Meijer DK; de Leij LF; Molema G
Int J Cancer; 2002 Dec; 102(5):469-75. PubMed ID: 12432548
[TBL] [Abstract][Full Text] [Related]
2. Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting.
Schraa AJ; Kok RJ; Berendsen AD; Moorlag HE; Bos EJ; Meijer DK; de Leij LF; Molema G
J Control Release; 2002 Oct; 83(2):241-51. PubMed ID: 12363450
[TBL] [Abstract][Full Text] [Related]
3. RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward alphavbeta3-expressing endothelial cells.
Schraa AJ; Kok RJ; Botter SM; Withoff S; Meijer DK; de Leij LF; Molema G
Int J Cancer; 2004 Nov; 112(2):279-85. PubMed ID: 15352041
[TBL] [Abstract][Full Text] [Related]
4. Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo.
Kluza E; Jacobs I; Hectors SJ; Mayo KH; Griffioen AW; Strijkers GJ; Nicolay K
J Control Release; 2012 Mar; 158(2):207-14. PubMed ID: 22079810
[TBL] [Abstract][Full Text] [Related]
5. Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics.
Kok RJ; Schraa AJ; Bos EJ; Moorlag HE; Asgeirsdóttir SA; Everts M; Meijer DK; Molema G
Bioconjug Chem; 2002; 13(1):128-35. PubMed ID: 11792188
[TBL] [Abstract][Full Text] [Related]
6. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
7. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
[TBL] [Abstract][Full Text] [Related]
8. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
9. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
10. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
11. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
12. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
13. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activity of targeted proapoptotic peptides.
Capello A; Krenning EP; Bernard BF; Breeman WA; Erion JL; de Jong M
J Nucl Med; 2006 Jan; 47(1):122-9. PubMed ID: 16391196
[TBL] [Abstract][Full Text] [Related]
15. Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.
DeNardo SJ; Burke PA; Leigh BR; O'Donnell RT; Miers LA; Kroger LA; Goodman SL; Matzku S; Jonczyk A; Lamborn KR; DeNardo GL
Cancer Biother Radiopharm; 2000 Feb; 15(1):71-9. PubMed ID: 10740655
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeled RGD uptake and alphav integrin expression is enhanced in ischemic murine hindlimbs.
Lee KH; Jung KH; Song SH; Kim DH; Lee BC; Sung HJ; Han YM; Choe YS; Chi DY; Kim BT
J Nucl Med; 2005 Mar; 46(3):472-8. PubMed ID: 15750161
[TBL] [Abstract][Full Text] [Related]
17. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis.
Chen X; Park R; Shahinian AH; Tohme M; Khankaldyyan V; Bozorgzadeh MH; Bading JR; Moats R; Laug WE; Conti PS
Nucl Med Biol; 2004 Feb; 31(2):179-89. PubMed ID: 15013483
[TBL] [Abstract][Full Text] [Related]
18. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model.
Smolarczyk R; Cichoń T; Graja K; Hucz J; Sochanik A; Szala S
Acta Biochim Pol; 2006; 53(4):801-5. PubMed ID: 17143339
[TBL] [Abstract][Full Text] [Related]
20. Endothelial expression of vascular cell adhesion molecule-1 correlates with metastatic pattern in spontaneous melanoma.
Langley RR; Carlisle R; Ma L; Specian RD; Gerritsen ME; Granger DN
Microcirculation; 2001 Oct; 8(5):335-45. PubMed ID: 11687945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
